Association of RXR-Gamma Gene Variants with Familial Combined Hyperlipidemia: Genotype and Haplotype Analysis

Table 1

Clinical characteristics of FCHL patients and controls.

	Controls (𝑛=119)	FCHL
		Probands (𝑛=74)	All affected (𝑛=192)
Age (yrs)	51.96±12.10	47.77±12.47^∗	49.81±14.83
Sex (M/F)	53/66	50/24**	111/81*
BMI (Kg/m^2)	24.83±3.69	26.47±3.64^∗∗	25.96±3.71^∗
Current smokers, 𝑛 (%)	—	22 (29.7%)	54 (28.1%)
Hypertension, 𝑛 (%)	27 (22.7%)	14 (18.9%)	37 (19.3%)
Blood glucose (mg/dL)	92.97±18.20	89.13±14.64	87.98±13.15^∗∗
Insulin (mUI/L)	16.76±19.18	11.70±8.51	11.41±6.86
HOMA index	3.53±4.14	2.59±2.17	2.49±1.77
Diabetes, 𝑛 (%)	4 (3.4%)	2 (2.7%)	6 (3.1%)
CAD, 𝑛 (%)	—	11 (14.9%)	29 (15.1%)
Plasma lipids (mg/dL)
TC	199.95±37.50	252.95±56.07^∗∗∗	251.61±46.25^∗∗∗
HDL-C	56.93±13.60	45.95±13.93^∗∗∗	48.21±14.42^∗∗∗
TG	104.81±56.72	270.64±131.77^∗∗∗	246.91±128.59^∗∗∗
LDL-C	122.05±32.3	155.58±52.5^∗∗∗	154.93±46.80^∗∗∗
ApoB	—	151.09±33.56	155.61±30.78

Data are reported as means ± SD.
BMI: body mass index; HOMA: homeostasis model assessment calculated according to Matthews et al. [12]; CAD: coronary artery disease; TC: total cholesterol; HDL-C: high density lipoprotein cholesterol; TG: total triglycerides; LDL-C: low density lipoprotein cholesterol; ApoB: apolipoprotein B; SD: standard deviation; FCHL: familial combined hyperlipidemia; M: male; F: female.
Probands were index cases of each 74 FCHL kindred.
 ^∗𝑃<0.05, ^∗∗𝑃<0.005, and ^∗∗∗𝑃<0.001 for comparison between controls and probands or all FCHL patients.